Skip to main content

Table 4 Regional percent of Aβ deposition per year in a sample of subject with SCD (n = 168, dataset #3)

From: Early detection of amyloid load using 18F-florbetaben PET

   Percent Aβ deposition per year
Method Region Aβ-negative Gray zone Established Aβ pathology
MRI-based ROIs Frontal − 0.01 ± 1.15 (p = 0.52) 1.08 ± 1.91 (p < 10−3) 2.72 ± 2.53 (p < 10−4)
Lateral temporal 0.08 ± 0.99 (p = 0.21) 1.07 ± 1.61 (p < 10−4) 2.05 ± 2.18 (p < 10−3)
Occipital 0.36 ± 1.13 (p < 10−3) 0.50 ± 1.74 (p = 0.38) 1.85 ± 2.18 (p < 10−3)
Parietal 0.12 ± 1.29 (p = 0.16) 1.39 ± 2.10 (p = 0.02) 2.61 ± 2.28 (p < 10−5)
Anterior cingulate 0.17 ± 1.81 (p = 0.13) 1.42 ± 2.12 (p = 0.10) 2.37 ± 3.07 (p = 0.001)
Posterior cingulate 0.71 ± 1.72 (p < 10−5) N.A 3.14 ± 2.46 (p < 10−7)
Precuneus 0.31 ± 1.37 (p = 0.006) N.A N.A
Composite 0.24 ± 1.24 (p = 0.02) 1.66 ± 1.86 (p < 10−3) 2.40 ± 2.37 (p < 10−3)
CL Cortex 0.00 ± 0.89 (p = 0.53) 1.81 ± 1.86 (p < 10−3) 2.38 ± 1.82 (p < 10−4)
  1. SCD subjective cognitive decline, N.A not available (As Aβ-negative, gray zone, and established Aβ pathology were defined regionally using cutoffs reported in Tables 2 and 3, there were not enough regional standardized uptake values (SUVRs) to calculate percent Aβ deposition per year in some regions), amyloid-beta, MRI magnetic resonance imaging, ROI region of interest, CL centiloid. p-values testing whether percent Aβ deposition per year is significantly larger than zero are given in parenthesis